Frenia50 ml

Frenia 50 ml is an atypical antipsychotic medicine prescribed for the management of a range of psychiatric conditions. It works by restoring the balance of natural chemical messengers (neurotransmitters) in the brain, helping to reduce disturbed thoughts, mood swings, and behavioural symptoms. Frenia 50 ml is indicated for the treatment of:

• Acute and chronic psychoses — conditions marked by a loss of contact with reality, including hallucinations and delusions.
• Mania — episodes of elevated mood, overactivity, and irritability, commonly seen in bipolar disorder.
• Schizophrenia — a long-term mental health disorder affecting thoughts, emotions, and behaviour, including both positive symptoms (such as hallucinations) and negative symptoms (such as social withdrawal).

* Always take this medication as directed by a registered physician.

Frenia 50 ml belongs to the class of atypical neuroleptic (antipsychotic) drugs.

Frenia 50 ml is a selective monoaminergic antagonist with a high affinity for serotonergic 5-HT₂ and dopaminergic D₂ receptors. It also binds to alpha₁-adrenergic receptors and, with lower affinity, to H₁ histaminergic and alpha₂-adrenergic receptors. Frenia 50 ml has no affinity for cholinergic receptors.

As a potent D₂ antagonist, Frenia 50 ml improves the positive symptoms of schizophrenia (such as hallucinations and delusions) while causing comparatively less suppression of motor activity than conventional antipsychotics. Its balanced antagonism of central serotonin and dopamine is thought to reduce the likelihood of extrapyramidal side effects and to extend therapeutic benefit to the negative and affective symptoms of schizophrenia, such as blunted emotion, social withdrawal, and depressed mood.

Frenia 50 ml may interact with several other medicines, altering their effects or its own. Notable interactions include:

• Levodopa and dopamine agonists: Frenia 50 ml may antagonise (reduce) their effects.
• Carbamazepine: Long-term (chronic) co-administration reduces the plasma clearance of Frenia 50 ml, which may affect its levels.
• Clozapine: Chronic co-administration may decrease the clearance of Frenia 50 ml.
• Antihypertensives: Frenia 50 ml may enhance the blood-pressure-lowering effects of certain antihypertensive medicines.

Inform your doctor about all prescription medicines, over-the-counter drugs, and supplements you are taking before starting Frenia 50 ml.

Like all medicines, Frenia 50 ml can cause side effects, although not everyone experiences them. Commonly reported side effects include insomnia, agitation, anxiety, and headache.

Less common side effects that have been reported include:

• Drowsiness, impaired concentration, and fatigue
• Blurred vision
• Constipation, nausea, vomiting, dyspepsia (indigestion), and abdominal pain
• Hyperprolactinaemia (raised prolactin levels) and urinary incontinence
• Tachycardia (rapid heartbeat), hypertension (raised blood pressure), and oedema (swelling)
• Skin rash and rhinitis (runny or blocked nose)
• Cerebrovascular accident (stroke)
• Neutropenia and thrombocytopenia (reductions in certain blood cells)

Consult your doctor if any side effect becomes severe, persistent, or troublesome.

Pregnancy: In experimental animals, Frenia 50 ml did not show direct reproductive toxicity, though some indirect, prolactin- and CNS-mediated effects were observed. No teratogenic (birth-defect-causing) effect was noted in any study. However, the safety of Frenia 50 ml during human pregnancy has not been established, so it should be used only if the potential benefit justifies the potential risk to the foetus.

Lactation: In animal studies, Frenia 50 ml and its active metabolite 9-hydroxyFrenia 50 ml are excreted in milk, and both have also been demonstrated to be excreted in human breast milk. Therefore, women receiving Frenia 50 ml should not breastfeed.

Special caution is required when using Frenia 50 ml in the following situations:

• Pre-existing cardiovascular (heart and blood vessel) diseases.
• Discontinue use if signs and symptoms of tardive dyskinesia (involuntary, repetitive body movements) occur.
• Renal (kidney) and hepatic (liver) impairment.
• Elderly patients.
• Epilepsy.
• Parkinson's disease.
• Pregnancy.

Patients and caregivers should be advised to report any unusual movements, mood changes, or other concerning symptoms to a physician promptly.

Drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms may occur. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers. There is no specific antidote to Frenia 50 ml.

Do not store above 30°C. Keep Frenia 50 ml away from light and out of the reach of children. Do not use the medicine after its expiry date.